Cancer Treatment: Selecting Patients Based On Genotype May Increase Efficacy Of Tamoxifen, Study Suggests
Wednesday, April 30, 2008 - 13:55
in Health & Medicine
Breast cancer patients who carry the wild-type gene required for tamoxifen metabolism may have comparable risk of recurrence when taking tamoxifen or an aromatase inhibitor, according to modeling data. Cytochrome P450 2D6 (CYP2D6) converts tamoxifen into its metabolically active form called endoxifen.
Read the whole article on Science Daily
More from Science Daily
Related
- Mayo Clinic research on tamoxifen leads to recommendation for CYP2D6 gene testSat, 13 Dec 2008, 12:28:28 EST
- Meta-analyses of global trials finds in favor of aromatase inhibitorsThu, 11 Dec 2008, 16:57:26 EST
- Identifying the potential for tamoxifen resistance in patientsWed, 10 Jun 2009, 16:43:34 EDT
- Novel basis identified for tamoxifen failureThu, 4 Dec 2008, 4:37:28 EST
- Mayo Clinic researchers find tamoxifen's power comes from endoxifenThu, 11 Dec 2008, 13:52:09 EST